NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 14.7% – Time to Sell?

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) traded down 14.7% during trading on Wednesday . The stock traded as low as $0.8531 and last traded at $0.8531. 931,449 shares were traded during trading, an increase of 337% from the average session volume of 213,025 shares. The stock had previously closed at $1.00.

Analyst Ratings Changes

A number of equities analysts have commented on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

NeuroSense Therapeutics Stock Down 14.7%

The firm’s fifty day simple moving average is $0.91 and its 200-day simple moving average is $1.07.

Hedge Funds Weigh In On NeuroSense Therapeutics

Hedge funds have recently made changes to their positions in the business. Two Sigma Investments LP purchased a new position in NeuroSense Therapeutics in the third quarter worth $26,000. Jane Street Group LLC acquired a new stake in shares of NeuroSense Therapeutics in the 2nd quarter worth $54,000. Squarepoint Ops LLC grew its stake in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares during the last quarter. Finally, Yorkville Advisors Global LP acquired a new position in NeuroSense Therapeutics during the 4th quarter valued at about $77,000. Institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.